Erika Frank

Erika Frank

Auto-generated profile, based on publicly available information

Erika Frank

Uppsala Clinical Research Center, Uppsala University , Dag Hammarskjölds Väg 38, 751 85 Uppsala

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 June 2026 in Journal of the American Heart Association
Verified
Journal Article
Open access
SKSacharias von Koch
Sacharias von Koch
EFErika Frank
Erika Frank
KGKatja Gabrysch
Katja Gabrysch
SJStefan James
Stefan James
MGMatthias Götberg
Matthias Götberg
DEDavid Erlinge
David Erlinge
Background: Drug‐coated balloons (DCB) are frequently used during percutaneous coronary intervention. Despite this there are limited data from studies comparing different types of DCB, particularly for a paclitaxel‐coated balloon (PCB) using urea as the excipient. This study aimed to assess the clinical efficacy of the PCB with urea compared with other frequently used DCB, attempting to emulate a target trial using observational data. Methods: SCAAR (Swedish Coronary Angiography and Angioplasty Registry) is a nationwide registry including data on all patients in Sweden undergoing coronary angiography. For this study, all procedures with DCB in Sweden between August 2021 and May 2024 were included. Propensity score weighted multivariable Cox regression analysis and Kaplan–Meier estimates were used to assess outcomes through 2 years. Results: A total of 1797 (27.7%) procedures with the PCB with urea and 4691 (72.3%) procedures with Other DCB were eligible for this analysis. DCB treatment was performed in a variety of patients and lesions including 32.4% diabetes, 64.2% acute coronary syndrome, 20.5% bifurcations and 33.0% in‐stent restenosis. After 2 years, the event rates for the PCB with urea and Other DCB were 16.4% versus 18.4% for major adverse cardiovascular events (hazard ratio [HR] 1.01 [95% CI 0.84–1.22]), 7.2% versus 8.2% for all‐cause mortality (HR 1.05 [95% CI 0.80–1.39]), 6.1% versus 8.0% for myocardial infarction (HR 0.81 [95% CI 0.59–1.11]), 14.6% versus 14.9% for new revascularization with percutaneous coronary intervention (HR 1.02 [95% CI 0.83–1.25]), 0.8% versus 1.3% for target lesion definite thrombosis (HR 0.93 [95% CI 0.41–2.11]), 7.4% versus 8.7% for target lesion revascularization (HR 0.95 [95% CI 0.70–1.29]), and 10.5% versus 11.3% for target vessel revascularization (HR 0.99 [95% CI 0.76–1.29]). Conclusions: In this analysis evaluating 2‐year clinical outcomes after DCB, in a broad patient population, the PCB with urea had comparable outcomes with other contemporary DCB. This data further support the safety and efficacy of the PCB with urea.

2 September 2026 in European Heart Journal Open
Verified
Journal Article
Open access
JAJulia Aulin
Julia Aulin
KSKarl Sjölin
Karl Sjölin
EFErika Frank
Erika Frank
JLJohan Lindbäck
Johan Lindbäck
LLLars Lind
Lars Lind
JBJoachim Burman
Joachim Burman
Aims: Circulating neuroinjury biomarkers such as neurofilament light chain (NFL) and glial fibrillary acidic protein (GFAP) have emerged as indicators of brain health. While NFL predicts stroke in patients with atrial fibrillation, its prognostic value in unselected elderly populations is uncertain. We investigated the associations of NFL and GFAP with cardiovascular events and death in community-dwelling older adults. Methods and results: Baseline plasma NFL and GFAP concentrations were determined using high-sensitivity Simoa® assays in 806 participants aged 75 years from the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) study. Cox regression models with sequential adjustment for demographics, comorbidities, renal function, and NT-proBNP assessed associations with ischaemic stroke, myocardial infarction, cardiovascular death, all-cause death, and major adverse cardiovascular events (MACE; stroke, myocardial infarction, and all-cause death). During a median follow-up of 10 years, 55 ischaemic strokes, 48 myocardial infarctions, 52 cardiovascular deaths, and 188 all-cause deaths occurred. Neurofilament light chain was not independently associated with ischaemic stroke or myocardial infarction and showed no independent association with cardiovascular death after adjustment including NT-proBNP. In contrast, higher NFL was independently associated with all-cause death (adjusted hazard ratio per doubling 1.91; 95% CI 1.49–2.46) and MACE (1.53; 95% CI 1.21–1.93), and improved discrimination for all-cause death beyond established risk factors. Glial fibrillary acidic protein was not associated with any outcome. Conclusion: In community-dwelling elderly individuals, higher NFL was associated with increased risk of death but not with specific cardiovascular events. These findings suggest that NFL reflects overall physiological vulnerability rather than discrete vascular risk.